Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
B-cell chronic lymphocytic leukemia (B-CLL), the most common leukemia in the Western world, occurs in two forms, aggressive (showing for the most part high ZAP-70 expression and unmutated IgH V H ) and indolent (showing low ZAP-70 expression and mutated IgH V H ). We found that miR-29a is up-regulated in indolent human B-CLL as compared with aggressive B-CLL and normal CD19 + B cells. To study the role of miR-29 in B-CLL, we generated Eμ- miR-29 transgenic mice overexpressing miR-29 in mouse B cells. Flow cytometric analysis revealed a markedly expanded CD5 + population in the spleen of these mice starting at 2 mo of age, with 85% (34/40) of miR-29 transgenic mice exhibiting expanded CD5 + B-cell populations, a characteristic of B-CLL. On average, 50% of B cells in these transgenic mice were CD5 positive. At 2 y of age the mice showed significantly enlarged spleens and an increase in the CD5 + B-cell population to ∼100%. Of 20 Eμ- miR-29 transgenic mice followed to 24–26 mo of age, 4 (20%) developed frank leukemia and died of the disease. These results suggest that dysregulation of miR-29 can contribute to the pathogenesis of indolent B-CLL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A microRNA expression signature of human solid tumors defines cancer gene targets
Volinia, S., Calin, G. A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510565103 · Cited by 5,697
Self-citationCalin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., Keating, M., Rai, K., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242606799 · Cited by 5,111 · cited 3×
“These findings indicated that microRNAs play important roles in CLL and that down-regulation of miR-15/16 and subsequent Bcl2 up-regulation contribute to CLL pathogenesis (7).”
Self-citationGenomic Aberrations and Survival in Chronic Lymphocytic Leukemia
Döhner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Kröber, A., Bullinger, L., Döhner, K., Bentz, M., & Lichter, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012283432602 · Cited by 3,318
Cited by
The role of non-coding RNAs in oncology
Slack, F. J., & Chinnaiyan, A. M. (2019) · Cell · doi:10.1016/j.cell.2019.10.017 · Cited by 1,619
MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy
Kasinski, A. L., & Slack, F. J. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3166 · Cited by 936
Bertoli, G., Cava, C., & Castiglioni, I. (2015) · Theranostics · doi:10.7150/thno.11543 · Cited by 815
The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury
Kriegel, A. J., Liu, Y., Fang, Y., Ding, X., & Liang, M. (2012) · Physiological Genomics · doi:10.1152/physiolgenomics.00141.2011 · Cited by 533
“Moreover, miR-29 transgenic mice develop an indolent B-cell chronic lymphocytic leukemia phenotype (69, 76).”
BackgroundVirus-Encoded microRNAs: An Overview and a Look to the Future
Kincaid, R. P., & Sullivan, C. S. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1003018 · Cited by 396
Clinical Applications for microRNAs in Cancer
Nana-Sinkam, S. P., & Croce, C. M. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.192 · Cited by 352
Self-citationThe Viral and Cellular MicroRNA Targetome in Lymphoblastoid Cell Lines
Skalsky, R. L., Corcoran, D. L., Gottwein, E., Frank, C. L., Kang, D., Hafner, M., Nusbaum, J. D., Feederle, R., Delecluse, H.-J., Luftig, M. A., et al. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002484 · Cited by 352
RNA virus microRNA that mimics a B-cell oncomiR
Kincaid, R. P., Burke, J. M., & Sullivan, C. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116107109 · Cited by 262
The role of miR-29b in cancer: regulation, function, and signaling
Yang, J.-R., Yan, B., Guo, Q., Fu, F.-J., Wang, Z., Yin, Z., & Wei, Y.-B. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s75899 · Cited by 198
“In addition, Santanam et al reported that the expression of miR-29 family members was higher in indolent human B-cell CLL (B-CLL) than in aggressive B-CLL and normal CD19+ B cells.(54) Kong et al demonstrated that miR-29a was upregulated in HCC induced by the hepatitis B virus X protein and promoted migration by targe…”
Small Non-Coding RNAs in Leukemia
Balatti, V., & Croce, C. M. (2022) · Cancers · doi:10.3390/cancers14030509 · Cited by 14
“As opposed to miR-181, miR-29 was found overexpressed in CLL cells from both indolent and aggressive cases when compared to normal B cells [63].”
Self-citationNoncoding RNAs in Retrovirus Replication
Duchon, A. A., & Musier-Forsyth, K. (2018) · Retrovirus-Cell Interactions · doi:10.1016/b978-0-12-811185-7.00012-1 · Cited by 1
“Interestingly, BLV-miR-B4 has an identical seed sequence to host miR-29, which has previously been implicated in transformation of B cells in mice, and is sufficient to induce tumor formation (Kincaid et al., 2012; Han et al., 2010; Santanam et al., 2010).”
Background
Metadata
- Authors
- Santanam, U., Zanesi, N., Efanov, A., Costinean, S., Palamarchuk, A., Hagan, J. P., Volinia, S., Alder, H., Rassenti, L., Kipps, T., Croce, C. M., & Pekarsky, Y.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2010-06-21
- Volume
- 107
- Issue
- 27
- Pages
- 12210-12215
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W4235498863
- Cited by
- 155
- References
- 3
- FWCI
- 7.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.